Yong-Feng Xu1, Yu Lu1, He Cheng1, Si Shi1, Jin Xu1, Jiang Long1, Liang Liu1, Chen Liu2, Xianjun Yu3. 1. Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, No. 270 DongAn Road, Shanghai 200032, PR China; Department of Oncology, Shanghai Medical College, Fudan University, No. 270 DongAn Road, Shanghai 200032, PR China; Pancreatic Cancer Institute, Fudan University, No. 270 DongAn Road, Shanghai 200032, PR China. 2. Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, No. 270 DongAn Road, Shanghai 200032, PR China; Pancreatic Cancer Institute, Fudan University, No. 270 DongAn Road, Shanghai 200032, PR China. Electronic address: blurlc@hotmail.com. 3. Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, No. 270 DongAn Road, Shanghai 200032, PR China; Department of Oncology, Shanghai Medical College, Fudan University, No. 270 DongAn Road, Shanghai 200032, PR China; Pancreatic Cancer Institute, Fudan University, No. 270 DongAn Road, Shanghai 200032, PR China. Electronic address: yuxianjun@fudan.edu.cn.
Abstract
BACKGROUND/ OBJECTIVES: The impairment of the immune system is prevalent in patients with malignancies, including pancreatic ductal adenocarcinoma (PDAC). The present study aimed to evaluate alternations of peripheral lymphocyte subsets in patients with PDAC, and also to assess the prognostic value of observed changes. METHODS: We recruited 160 consecutive PDAC patients who had undergone radical surgical resection between 2010 and 2013. To investigate the prognostic factors, we detected the peripheral lymphocyte subsets in PDAC by flow cytometry, including T cells (CD3(+), CD3(+)CD4(+), CD3(+)CD8(+), CD8(+)CD28(+)), regulatory T cells (Tregs, CD4(+)CD25(+)CD127(-)), natural killer cells (NK cells, CD3(-)CD56(+)) and B cells (CD19(+)). We also evaluated the clinical and pathological features of these patients. Survival analysis was performed by univariate and multivariate analyses. RESULTS: Our results indicated the profile of peripheral lymphocyte subsets undergone profound changes in PDAC patients. Univariate and multivariate analysis indicated the levels of peripheral lymphocyte subsets (CD19(+) B cells, Tregs and CD8(+)CD28(+) T cells) were independent predictors for overall survival. The results also suggested that the systemic impairment of immune system in patients with PDAC, was reversed when primary tumor was removed. CONCLUSIONS: The present study provided some evidences that the impairment of host immunity induced by PDAC may play a role in the survival of patients.
BACKGROUND/ OBJECTIVES: The impairment of the immune system is prevalent in patients with malignancies, including pancreatic ductal adenocarcinoma (PDAC). The present study aimed to evaluate alternations of peripheral lymphocyte subsets in patients with PDAC, and also to assess the prognostic value of observed changes. METHODS: We recruited 160 consecutive PDACpatients who had undergone radical surgical resection between 2010 and 2013. To investigate the prognostic factors, we detected the peripheral lymphocyte subsets in PDAC by flow cytometry, including T cells (CD3(+), CD3(+)CD4(+), CD3(+)CD8(+), CD8(+)CD28(+)), regulatory T cells (Tregs, CD4(+)CD25(+)CD127(-)), natural killer cells (NK cells, CD3(-)CD56(+)) and B cells (CD19(+)). We also evaluated the clinical and pathological features of these patients. Survival analysis was performed by univariate and multivariate analyses. RESULTS: Our results indicated the profile of peripheral lymphocyte subsets undergone profound changes in PDACpatients. Univariate and multivariate analysis indicated the levels of peripheral lymphocyte subsets (CD19(+) B cells, Tregs and CD8(+)CD28(+) T cells) were independent predictors for overall survival. The results also suggested that the systemic impairment of immune system in patients with PDAC, was reversed when primary tumor was removed. CONCLUSIONS: The present study provided some evidences that the impairment of host immunity induced by PDAC may play a role in the survival of patients.
Authors: Jack Hutcheson; Uthra Balaji; Matthew R Porembka; Megan B Wachsmann; Peter A McCue; Erik S Knudsen; Agnieszka K Witkiewicz Journal: Clin Cancer Res Date: 2016-02-08 Impact factor: 12.531
Authors: Eunsung Jun; Ah Young Song; Ji-Wan Choi; Hyeon Ho Lee; Mi-Yeon Kim; Dae-Hyun Ko; Hyo Jeong Kang; Seong Who Kim; Yenan Bryceson; Song Cheol Kim; Hun Sik Kim Journal: Front Immunol Date: 2019-06-21 Impact factor: 7.561
Authors: Iman M Ahmad; Alicia J Dafferner; Kelly A O'Connell; Kamiya Mehla; Bradley E Britigan; Michael A Hollingsworth; Maher Y Abdalla Journal: Cancers (Basel) Date: 2021-05-08 Impact factor: 6.639
Authors: Michael Karl Melzer; Frank Arnold; Katja Stifter; Friedemann Zengerling; Ninel Azoitei; Thomas Seufferlein; Christian Bolenz; Alexander Kleger Journal: Int J Mol Sci Date: 2020-05-08 Impact factor: 5.923